/
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Renal Pelvis and Ureter Urothelial Carcinoma is an emerging landscape with 11 programs across 8 companies.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Analysis
60%
Small molecule
6 of 10 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 91% of 11 pipeline programs.
Analysis
3
clinical trials
Clinical Trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)